Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Current Assets (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Current Assets for 11 consecutive years, with $134.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 760.06% to $134.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $134.6 million, a 760.06% increase, with the full-year FY2023 number at $43.8 million, down 13.65% from a year prior.
  • Current Assets was $134.6 million for Q3 2025 at Crescent Biopharma, down from $154.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $154.2 million in Q2 2025 to a low of $6.0 million in Q1 2025.
  • A 5-year average of $71.3 million and a median of $60.8 million in 2022 define the central range for Current Assets.
  • Biggest YoY gain for Current Assets was 760.06% in 2025; the steepest drop was 81.99% in 2025.
  • Crescent Biopharma's Current Assets stood at $90.8 million in 2021, then tumbled by 44.14% to $50.7 million in 2022, then fell by 13.65% to $43.8 million in 2023, then plummeted by 64.27% to $15.6 million in 2024, then surged by 760.06% to $134.6 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Current Assets are $134.6 million (Q3 2025), $154.2 million (Q2 2025), and $6.0 million (Q1 2025).